TY - JOUR T1 - The frequency of prescribing antimicrobial drugs in the initial therapy of COVID-19 at the outpatient stage JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3675 VL - 58 IS - suppl 65 SP - PA3675 AU - Roman Bontsevich AU - Vsevolod Vinyukov AU - Tatyana Subina AU - Yana Vovk AU - Diana Dubonosova Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3675.abstract N2 - Background: SARS-Cov2 (COVID-19) is a viral infection that does not require antimicrobial drugs (AMD) for an uncomplicated course of this disease. However, in a large number of cases outpatient doctors prescribe these drugs as an initial therapy.The aim: of study was to analyze the frequency of prescribing AMD in the initial therapy of patients with COVID-19 at the outpatient stage (non-severe patients).Material and methods: We carried out a case records’ retrospective analysis of the Belgorod outpatient clinic, in which patients received therapy of Covid-19 in an outpatient setting. The diagnosis of Covid-19 was confirmed by nucleic acid sequence based amplification (PCR of naso-oropharyngeal smear). The appointment of any systemic AMDs at the 1st stage of therapy in such patients was taken into account.Results: We analyzed 69 outpatient cards (36.2% men, 63.8% women). The overall frequency of prescribing AMDs was - 30.4%, monotherapy accounted for 98.6% of prescriptions, combined therapy – 1.4%. Most often, doctors prescribed: azithromycin – 15.9%, levofloxacin – 5.8%, ceftriaxone – 5.8%, amoxicillin/clavulanat – 1.4%, cefditoren -1.4%.Conclusions: Despite the fact that bacterial co-infection occurs in less than 10% of cases with Covid-19 in the first weeks of the disease, doctors often prescribe AMDs unreasonably. Additional educational and administrative work is required for physicians caring for patients with Сovid-19.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3675.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -